JP2024509501A5 - - Google Patents

Info

Publication number
JP2024509501A5
JP2024509501A5 JP2023544261A JP2023544261A JP2024509501A5 JP 2024509501 A5 JP2024509501 A5 JP 2024509501A5 JP 2023544261 A JP2023544261 A JP 2023544261A JP 2023544261 A JP2023544261 A JP 2023544261A JP 2024509501 A5 JP2024509501 A5 JP 2024509501A5
Authority
JP
Japan
Application number
JP2023544261A
Other languages
Japanese (ja)
Other versions
JP2024509501A (ja
JPWO2022165258A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014423 external-priority patent/WO2022165258A1/en
Publication of JP2024509501A publication Critical patent/JP2024509501A/ja
Publication of JP2024509501A5 publication Critical patent/JP2024509501A5/ja
Publication of JPWO2022165258A5 publication Critical patent/JPWO2022165258A5/ja
Pending legal-status Critical Current

Links

JP2023544261A 2021-01-28 2022-01-28 新規活性を持つhhla2結合剤 Pending JP2024509501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142832P 2021-01-28 2021-01-28
US63/142,832 2021-01-28
PCT/US2022/014423 WO2022165258A1 (en) 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity

Publications (3)

Publication Number Publication Date
JP2024509501A JP2024509501A (ja) 2024-03-04
JP2024509501A5 true JP2024509501A5 (https=) 2025-02-04
JPWO2022165258A5 JPWO2022165258A5 (https=) 2025-02-04

Family

ID=82652818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544261A Pending JP2024509501A (ja) 2021-01-28 2022-01-28 新規活性を持つhhla2結合剤

Country Status (11)

Country Link
US (1) US20250270323A1 (https=)
EP (1) EP4284431A4 (https=)
JP (1) JP2024509501A (https=)
KR (1) KR20230135637A (https=)
CN (1) CN116981476A (https=)
AU (1) AU2022214939A1 (https=)
BR (1) BR112023014826A2 (https=)
CA (1) CA3207494A1 (https=)
IL (1) IL304584A (https=)
MX (1) MX2023008182A (https=)
WO (1) WO2022165258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326764A (en) * 2023-09-08 2026-04-01 Nextpoint Therapeutics Inc Antibody-drug conjugates
CN119841949A (zh) * 2023-10-17 2025-04-18 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280208B2 (en) * 2014-04-30 2019-05-07 Albert Einstein College Of Medicine TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
KR20210007959A (ko) * 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도

Similar Documents

Publication Publication Date Title
CL2025003847A1 (es) Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13135U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
CN307044559S (https=)